Pfizer Corp - רווח נקי למניה (EPS TTM) PFE

Pfizer Inc. (PFE) is updating its portfolio, replacing declining COVID vaccines with innovative oncology drugs. This strategy relies on aggressive M&A deals to shift its growth vector. Global distribution reach and capital allow the behemoth to acquire biotech startups, creating future monopolies. The TTM annual earnings per share illustrates this fundamental resilience, with the latest figure standing at 0.70.

This indicator measures the total net income of Pfizer Inc. (PFE) over the last four quarters, distributed per common share to determine the actual return on equity. By analyzing the annual net income per share trend, an investor assesses the resilience of the defensive business of Pfizer Inc. (PFE), where payment stability is ensured by patents and demand for drugs regardless of market conditions.